These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33209877)

  • 1. Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations.
    Wang Y; Li J; Zhou Y; Cao S; Ling X; Zhang Y; Nie W; Zhong H
    Ann Transl Med; 2020 Oct; 8(20):1297. PubMed ID: 33209877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with
    Xu CW; Wang WX; Wang D; Wang QM; Pu XX; Zhu YC; Huang JH; Yu ZY; Cui ZL; Chen XH; Li JL; Fang Y; Wang H; Zhuang W; Lan SJ; Cai X; Zhang YB; Gao WB; Wang LP; She KL; Rao CZ; Zhou YF; Fang MY; Miao LY; Lei L; Lv TF; Song Y
    Transl Lung Cancer Res; 2020 Oct; 9(5):1853-1861. PubMed ID: 33209607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.
    Wang H; Xu Y; Lin J; Huang Y
    Cancer Control; 2024; 31():10732748241262190. PubMed ID: 38857163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
    Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
    Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer.
    Gao X; Wei XW; Zheng MY; Chen ZH; Zhang XC; Zhong WZ; Yang JJ; Wu YL; Zhou Q
    J Thorac Dis; 2020 Oct; 12(10):5822-5832. PubMed ID: 33209414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
    Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
    Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Yang G; Yang Y; Hu J; Xu H; Zhang S; Wang Y
    Front Pharmacol; 2022; 13():984503. PubMed ID: 36425568
    [No Abstract]   [Full Text] [Related]  

  • 8. EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
    Shah MP; Aredo JV; Padda SK; Ramchandran KJ; Wakelee HA; Das MS; Neal JW
    Clin Lung Cancer; 2022 Mar; 23(2):e148-e153. PubMed ID: 34391686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: sequential use of almonertinib based on the
    Wang R; Yu S; Yu L; Zhao J; Jiao S; Wang Q; Wu Y
    Transl Cancer Res; 2022 Jun; 11(6):1836-1843. PubMed ID: 35836508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with
    Shi C; Xing R; Li M; Feng J; Sun R; Wei B; Guo Y; Ma J; Wang H
    Front Oncol; 2022; 12():949304. PubMed ID: 36119499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR exon 20 insertion mutations in non-small cell lung cancer.
    Wang F; Li C; Wu Q; Lu H
    Transl Cancer Res; 2020 Apr; 9(4):2982-2991. PubMed ID: 35117654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Clinical Outcomes for Patients with
    Li K; Bosdet I; Yip S; Ho C; Laskin J; Melosky B; Wang Y; Sun S
    Curr Oncol; 2023 Jul; 30(8):7099-7111. PubMed ID: 37622996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis.
    Zhang M; Huang Q; Yu M; Xue J; Huang M; Lu Y; Zhang Y
    Transl Lung Cancer Res; 2023 Apr; 12(4):797-807. PubMed ID: 37197626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with
    Metro G; Baglivo S; Bellezza G; Mandarano M; Gili A; Marchetti G; Toraldo M; Molica C; Reda MS; Tofanetti FR; Siggillino A; Prosperi E; Giglietti A; Di Girolamo B; Garaffa M; Marasciulo F; Minotti V; Gunnellini M; Guida A; Sassi M; Sidoni A; Roila F; Ludovini V
    Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33946594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
    Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
    Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
    Minchom A; Viteri S; Bazhenova L; Gadgeel SM; Ou SI; Trigo J; Bauml JM; Backenroth D; Bhattacharya A; Li T; Mahadevia P; Girard N
    Lung Cancer; 2022 Jun; 168():74-82. PubMed ID: 35597172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
    Wu JY; Yu CJ; Shih JY
    Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
    Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
    Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
    Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
    BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.